Introduction
Gram-negative bacteria are common causes of intra-abdominal infections and urinary tract infections, and resistance amongst these pathogens is increasing. 1 Eravacycline (ERV) is a novel, fully-synthetic fl uorocycline antibiotic of the tetracycline class in development for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. ERV is in phase 3 clinical development for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI), including pyelonephritis.
The purpose of this study was to evaluate activity of ERV and comparators against global isolates of Enterobacteriaceae (ENT), A. baumannii (AB), and S. maltophilia (SM), including those resistant to carbapenems (CR) or 3rd/4th generation cephalosporins (ESC-R), over a three-year surveillance period. ■ Clinical isolates were from global locations, with 48% from countries within North America (specifi cally, the United States), 41% from within Europe, 7% from within Asia, and 4% from within the South Pacifi c (Fig. 1 ).
Methods
■ Most isolates were collected from respiratory, GI, GU, and bodily fl uid sources followed by skin/wound infections ( Fig. 2 ).
■ Minimal inhibitory concentration (MIC) endpoints were determined by broth microdilution according to CLSI guidelines. 2 ■ Quality control testing was performed each day of testing as specifi ed by the CLSI using Escherichia coli ATCC 25922, E. coli ATCC 35218 and P. aeruginosa ATCC 27853.
■ Antibiotic susceptibility was determined using CLSI 2015 breakpoints 3 , with the exception of tigecycline (TGC), where FDA breakpoints were used. 4 ■ MDR was defi ned as resistant to at least 1 agent in 3 or more antibiotic categories.
■ ESC-R was defi ned as resistant to ceftriaxone, cefotaxime, ceftazidime, or cefepime.
■ CR was defi ned as resistant to imipenem (2013-2014 isolates) or meropenem (2015 isolates).
Results (cont'd)

Conclusions
■ ERV demonstrated consistent and potent activity against ENT, AB, and SM over a recent 3-year time period (2013) (2014) (2015) .
■ ERV shows promising activity against globally-isolated Gram-negative organisms, including those with resistant phenotypes. Table 1) . The MIC 90 values against MDR (Table 2) and ESC-R (Table 3) were identical to the combined population.
-Amongst most ENT pathogens, ERV MIC 90 values increased by 1 doubling-dilution for resistant phenotypes (Tables 1-4 ).
- (Table 2) .
■ Based on MIC 90 values, the potency of ERV was up to 4-fold greater than that of TGC against these Gram-negative organisms.
■ Cumulative MIC distribution patterns for ENT organisms were relatively consistent over the three-year period (Fig. 3) . A one doubling-dilution shift was seen for SM and AB in the 0.12 -1 mg/L ranges from 2013 to 2015. For both organisms, the number of 2014 isolates was low compared with 2015.
